Baird Capital’s Virtual Incision Announces Final Stage of FDA Approval for MIRA®
Baird Capital portfolio company Virtual Incision today announced the FDA has approved an Investigational Device Exemption (IDE) supplement to complete the final stage of its clinical study analyzing the MIRA® Platform in bowel resection procedures. MIRA is a first-of-its-kind miniaturized surgical robotic support device, focusing first on colon resection, with follow-on specialty robots for additional potential applications.
The IDE supplement approval puts Virtual Incision on track to obtain the clinical evidence needed to bring new innovation to the soft tissue surgical robotics industry, a market that has been historically dominated by a single player. Results of the completed study will support MIRA’s upcoming FDA De Novo application for market authorization.
The Venture Capital team announced its initial investment in December 2021. Headquartered in Lincoln, Neb., Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients.